Spectratox Ltd. was launched in 2008. Its sole shareholder is the Photobiology
Trust, a charitable organisation devoted to the promotion of dermatological
research, education and clinical care. Any surplus study funds are used
for the benefit of patients. Spectratox is a limited company and is independent
of the National Health Service.
Spectratox is driven by the expertise and reputations of Professor James
Ferguson and Professor Harry Moseley. Together they have
developed an evidence-based methodology for studying phototoxicity
in clinical volunteers. Professor Ferguson has 20 years experience advising
on the need for such work.
- Professor James Ferguson, MD, FRCP, is
a renowned academic clinician who has published widely
in the areas of drug-induced phototoxicity, phototherapy,
photochemotherapy and the photodermatoses. (See Publications.)
Harry Moseley, PhD, FInstP, provides the essential
photophysics expertise. He has an international reputation
in the field of UV spectroscopy and development of new UV measurement
techniques. His publications cover UV dosimetry, assessment of sunscreens
and clothing, dermatological laser applications. etc. (See Publications.)
The staff at Spectratox are also expert in:
- Pre-clinical laboratory data analysis.
- Clinical ‘healthy volunteer’ studies and post-study testing.
- Advice on product labelling
and clinical management.
Phototoxicity testing is carried out on the premises of the National Photobiology
Unit, Ninewells Hospital and Medical School, a part of NHS
Tayside (but, please note, Spectratox Ltd. is completely
independent of the NHS.)
From left to right Professor James
Ferguson, Professor Harry Moseley and Dr Robert Dawe